Skip to main content

Table 1 Baseline characteristics of coronary artery disease (CAD) patients according to the outcome during follow-up

From: Association of soluble endothelial protein C receptor plasma levels and PROCR rs867186 with cardiovascular risk factors and cardiovascular events in coronary artery disease patients: The Athero Gene Study

Characteristics

No cardiovascular event n=1537

Cardiovascular event n=136

Association Test

Age, years

61.2 Ā± 9.5

62.8 Ā± 10.5

p = 0.059

Females

323 (21 %)

39 (29%)

p = 0.050

Acute coronary syndrome

467 (30 %)

58 (43 %)

p = 3.78 10-3

Previous myocardial infarction

586 (38 %)

65 (48 %)

p = 0.028

Number of stenosed coronary arteries

Ā Ā Ā 

ā€ƒā€‰one vessel

438 (29 %)

21 (15 %)

Ā 

ā€ƒā€‰two vessels

479 (31 %)

43 (32 %)

p = 1.31 10-3

ā€ƒā€‰three vessels

620 (40 %)

72 (53 %)

Ā 

Body mass index (kg/m2)

27.7 Ā± 3.9

27.8 Ā± 3.8

p = 0.927

Current smoker

304 (20 %)

33 (24 %)

p = 0.219

Diabetes mellitus

240 (16 %)

43 (32 %)

p = 1.17 10-5

Hypertension

1151 (75 %)

105 (77 %)

p = 0.606

Medications at enrollment

Ā Ā Ā 

ā€ƒā€‰Heparin

521 (34 %)

55 (40 %)

p = 0.132

ā€ƒā€‰Antiplatelet therapy

1327 (86 %)

108 (79 %)

p = 0.039

ā€ƒā€‰Statins

800 (52 %)

68 (50 %)

p = 0.277

ā€ƒā€‰Beta-blocker

1026 (67 %)

80 (59 %)

p = 0.072

ā€ƒā€‰ACE-inhibitor

770 (50 %)

84 (62 %)

p = 9.41 10-3

ā€ƒā€‰Calcium antagonists

197 (13 %)

25 (18 %)

p = 0.085

Total cholesterol (mgdL-1)

197 Ā± 45

205 Ā± 51

p = 0.038

HDL-cholesterol (mgdL-1)

49.4 Ā± 13.5

48.1 Ā± 13.6

p = 0.290

Triglyceride (mgdL-1)

129 (95ā€“182)

130 (100ā€“183)

p = 0.143

CRP (mgL-1)

2.39 (1.02 - 6.14)

4.59 (1.89 - 11.7)

p = 8.41 10-6

Fibrin monomers (Ī¼mL)

3.90 (2.64 - 5.33)

3.32 (2.64 - 5.34)

p = 0.514

D-dimers (Ī¼gmL-1)

0.34 (0.24 - 0.52)

0.39 (0.25 - 0.78)

p = 0.024

t-TAFI (Ī¼g mL-1)

12.0 Ā± 2.7

12.4 Ā± 2.7

p = 0.196

TAFIa/TAFIai (ngmL-1)

10.48 (8.13 - 13.95)

11.59 (9.00 - 15.08)

p = 2.75 10-3

Soluble Tissue factor (pgmL-1)

158 (124ā€“204)

159 (124ā€“208)

p = 0.641

f-TFPI (ngmL-1)

10.80 (7.61 - 18.89)

13.46 (9.34 - 25.89)

p = 7.54 10-3

Creatinine (mgdL-1)

0.96 Ā± 1.03

1.03 Ā± 0.29

p = 5.59 10-4

Cystatin C (mgL-1)

0.81 (0.71 - 0.94)

0.86 (0.72 - 1.08)

p = 1.28 10-4

sEPCR(ngmL-1)

114 (93ā€“161)

110 (91ā€“177)

p = 0.654

  1. t-TAFI measures total Thrombin Activating Fibrinolysis Inhibitor in plasma ; TAFIa/TAFIai measures activated TAFI levels in plasma; f-TFPI = free form of tissue factor pathway inhibitor 1.
  2. Categorical variables are presented as n (%), and continuous variables as mean Ā± SD or median (25th - 75th percentile) for skewed variables (for these variables, tests were performed on log-transformed distribution).
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us